KathleenAnneNevilleMDMS, MBA

Pediatric Hematology & Oncology • Raritan, NJ

Hospice and Palliative Medicine(Pediatric Hematology and Oncology), Pediatric Anemia and Red Blood Cell Hematology, Pediatric Coagulation Disorder Hematology, Clinical Pharmacology

Sr. Director, Child Health Innovation Leadership Department, Johnson and Johnson.

Join to view full profile

Dr. Neville is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Neville's full profile

Already have an account?

Office
920 US-202 S
Raritan, NJ 08869
Is this information wrong?

Education & Training

Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 1998 - 2001
Brown UniversityResidency, Pediatrics, 1995 - 1998
State University of New York Downstate Medical Center College of MedicineClass of 1995

Certifications & Licensure

AR State Medical License 2015 - 2024
MO State Medical License 2005 - 2016
KS State Medical License 2005 - 2016
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Fellow (FAAP) American Academy of Pediatrics

Clinical Trials

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma Start of enrollment: 2008 Jan 14
Completed
Phase 2
External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas Start of enrollment: 2009 Oct 30
Completed
Phase 2
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors Start of enrollment: 2011 Feb 09
Completed
Phase 1, Phase 2
Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets Start of enrollment: 2011 Jul 01
Completed
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL Start of enrollment: 2011 Dec 01
Terminated
Phase 1, Phase 2
Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma Start of enrollment: 2011 Dec 01
Terminated
Phase 1, Phase 2
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma Start of enrollment: 2011 Dec 01
Completed
Phase 2
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma Start of enrollment: 2011 Dec 01
Terminated
Phase 1, Phase 2
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission Start of enrollment: 2012 Jun 01
Active, not recruiting
Phase 2
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) Start of enrollment: 2013 May 06
Completed
Phase 2
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12
Completed
Phase 2
Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer Start of enrollment: 2013 Feb 01
Active, not recruiting
Not Applicable
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. Start of enrollment: 2013 Aug 20
Completed
Phase 2
Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma Start of enrollment: 2014 May 01
Active, not recruiting
Phase 1, Phase 2
Molecular-Guided Therapy for Childhood Cancer Start of enrollment: 2014 Jul 08
Completed
Not Applicable
Trial of Tolcapone With Oxaliplatin for Neuroblastoma Start of enrollment: 2015 Dec 01
Terminated
Phase 1
Neuroblastoma Maintenance Therapy Trial Start of enrollment: 2016 Feb 01
Recruiting
Phase 2
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma Start of enrollment: 2020 Sep 25
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

8 citations
Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
Sara A. Byron, William P.D. Hendricks, Abhinav Nagulapally, Jacqueline M. Kraveka, William S. Ferguson, Valerie I. Brown, Don E Eslin, Deanna Mitchell, Albert Corneliu...> ;Cancer Research. 2021 Oct 5
2 citations
Capacity Building for Primary Stroke Prevention Teams in Children Living With Sickle Cell Anemia in Africa
Djamila L. Ghafuri, Brittany Covert Greene, Bilya Sani Musa, Awwal Gambo, Abdulrasheed Sani, Shehu U. Abdullahi, Binta J. Wudil, Halima Bello-Manga, Safiya Gambo, Mati...> ;Pediatric Neurology. 2021 Dec 1
33 citations
Moderate fixed‐dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial
Najibah A. Galadanci, Shehu U. Abdullahi, Shehi Abubakar, Binta W. Jibir, Hauwa Aminu, Aliyu Tijjani, Muhammad S. Abba, Musa A. Tabari, Aisha Amal Galadanci, Awwal Mus...> ;American Journal of Hematology. 2020 Sep 1
24 citations
Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers.
Glenson Samuel, Jennifer Crow, Jon B. Klein, Michael L. Merchant, Emily Nissen, Devin C. Koestler, Kris Laurence, Xiaobo Liang, Kathleen A. Neville, Atif A. Ahmed, Saf...> ;Oncotarget. 2020 Aug 4
4 citations
Measuring hydroxyurea adherence by pharmacy and laboratory data compared with video observation in children with sickle cell disease
Susan E Creary, Deena J. Chisolm, Joseph Stanek, Kathleen A. Neville, Uttam Garg, Jane S. Hankins, Sarah H. O'Brien> ;Pediatric Blood & Cancer. 2020 May 9
67 citations
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
Franco Locatelli, Christine Mauz-Koerholz, Kathleen A. Neville, Anna Llort, Auke Beishuizen, Stephen Daw, Marta Pillon, Nathalie Aladjidi, Thomas Klingebiel, Judith La...> ;The Lancet. Haematology. 2018 Oct 1
58 citations
Maintenance DFMO Increases Survival in High Risk Neuroblastoma
Giselle Saulnier Sholler, William S. Ferguson, Genevieve Bergendahl, Jeffrey P. Bond, Kathleen A. Neville, Don Eslin, Valerie I. Brown, William Roberts, Randal K. Wada...> ;Scientific Reports. 2018 Sep 27
6 citations
Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure
Jeremie H. Estepp, Paweł Wiczling, Joseph Moen, Guolian Kang, Joana M. Mack, Robert I. Liem, Julie A. Panepinto, Uttam Garg, Gregory L. Kearns, Kathleen A. Neville> ;British Journal of Clinical Pharmacology. 2018 Jul 1
18 citations
Comparative oncology approach to drug repurposing in osteosarcoma.
Alejandro Parrales, Peter R. McDonald, Megan Ottomeyer, Anuradha Roy, Frank J. Shoenen, Melinda Broward, Tyce Bruns, Douglas H. Thamm, Scott Weir, Kathleen A. Neville,...> ;Plos One. 2018 Mar 26
15 citations
Erratum to: Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial) (American Journal of Hematology, (2017), 92, 8,...
Najibah A. Galadanci, Shehu U. Abdullahi, Leah D. Vance, AM Tabari, Shehi Ali, Raymond Belonwu, Auwal Salihu, Aisha Amal Galadanci, Binta W. Jibir, Halima Bello-Manga,...> ;American Journal of Hematology. 2018 Mar 1
3 citations
Pharmacokinetics of two 6-mercaptopurine liquid formulations in children with acute lymphoblastic leukemia.
Jaszianne A. Tolbert, Shasha Bai, Susan M. Abdel-Rahman, Keith J. August, Scott Weir, Gregory L. Kearns, Kathleen A. Neville> ;Pediatric Blood & Cancer. 2017 Aug 1
18 citations
Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).
Najibah A Galadanci, Shehu Umar Abdullahi, Leah D Vance, Abdulkadir Musa Tabari, Shehi Ali, Raymond Belonwu, Auwal Salihu, Aisha Amal Galadanci, Binta Wudil Jibir, Hal...> ;American Journal of Hematology. 2017 Aug 1
5 citations
Palatability of a novel oral formulation of prednisone in healthy young adults
Shasha Bai, Nathan Henry Dormer, Catherine Shoults, Amanda Meyer, Carol D Ann Pierce, Kathleen A. Neville, Gregory L. Kearns> ;The Journal of Pharmacy and Pharmacology. 2017 Mar 8
30 citations
In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma
Ziyan Y. Pessetto, Bin Chen, Hani J. Alturkmani, Stephen Hyter, Colleen A. Flynn, Michael Baltezor, Yan Ma, Howard G. Rosenthal, Kathleen A. Neville, Scott Weir, Atul ...> ;Oncotarget. 2017 Jan 17
118 citations
Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy
Pablo Angulo, Gaurav Kaushik, Dharmalingam Subramaniam, Prasad Dandawate, Kathleen A. Neville, Katherine Chastain, Shrikant Anant> ;Journal of Hematology & Oncology. 2017 Jan 7
2 citations
The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy.
Rita Secola, Araz Marachelian, Susan L. Cohn, Bonnie Toy, Kathleen A. Neville, Meaghan Granger, Angela Brentlinger, Gina Martin> ;Journal of Pediatric Oncology Nursing. 2017 Jan 6
5 citations
Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models
Elizabeth Marek, Jeremiah D. Momper, Ronald N. Hines, Cheryl Takao, Joan Cox Gill, Vera Pravica, Andrea Gaedigk, Gilbert J. Burckart, Kathleen A. Neville> ;The Journal of Pediatric Pharmacology and Therapeutics. 2016 Jul 20
13 citations
Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia
Jeremie H. Estepp, Chiara Melloni, Courtney D. Thornburg, Paweł Wiczling, Zora R. Rogers, Jennifer A. Rothman, Robert I. Liem, Amanda M. Brandow, Shelley E. Crary, Tho...> ;Journal of Clinical Pharmacology. 2016 Mar 1
17 citations
Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy.
Araz Marachelian, Ami V. Desai, Frank M. Balis, Howard M. Katzenstein, Muna Qayed, Michael B. Armstrong, Kathleen A. Neville, Susan L. Cohn, Mark Bush, Rudy Gunawan, A...> ;Cancer Chemotherapy and Pharmacology. 2016 Jan 20
3 citations
Pharmacotherapy of Sickle Cell Disease in Children.
Kathleen A. Neville, Julie A. Panepinto> ;Current Pharmaceutical Design. 2015 Nov 30
19 citations
Feasibility of implementing molecular‐guided therapy for the treatment of patients with relapsed or refractory neuroblastoma
Giselle Saulnier Sholler, Jeffrey P. Bond, Genevieve Bergendahl, Akshita Dutta, Julie A. Dragon, Kathleen A. Neville, William S. Ferguson, William Roberts, Don Eslin, ...> ;Cancer Medicine. 2015 Jun 1
10 citations
Isotope-dilution gas chromatography-mass spectrometry method for the analysis of hydroxyurea.
Uttam Garg, David T. Scott, Clint Frazee, Gregory L. Kearns, Kathleen A. Neville> ;Therapeutic Drug Monitoring. 2015 Jun 1
100 citations
A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
Giselle Saulnier Sholler, Eugene W. Gerner, Genevieve Bergendahl, Robert B. MacArthur, Alyssa VanderWerff, Takamaru Ashikaga, Jeffrey P. Bond, William S. Ferguson, Wil...> ;Plos One. 2015 May 27
10 citations
Developmental Changes of Normal Pupil Size and Reactivity in Children.
Jacob T. Brown, Mark Connelly, Caitlin Nickols, Kathleen A. Neville> ;Journal of Pediatric Ophthalmology and Strabismus. 2015 Mar 23
31 citations
Primary Stroke Prevention in Nigerian Children with Sickle Cell Disease (SPIN): Challenges of Conducting a Feasibility Trial
Najibah A. Galadanci, Shehu U. Abdullahi, Musa A. Tabari, Shehi Abubakar, Raymond Belonwu, Auwal Salihu, Kathleen A. Neville, Fenella J. Kirkham, Baba Inusa, Yu Shyr, ...> ;Pediatric Blood & Cancer. 2015 Mar 1
Join now to see all

Lectures

Drug Development and Implementation
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

Pediatric Labeling for OxyContin: Pros & ConsSeptember 1st, 2016
F.D.A. Approval of OxyContin for Children Continues to Draw ScrutinyJanuary 13th, 2016